ATP6V1F is a novel prognostic biomarker and potential immunotherapy target for hepatocellular carcinoma

Abstract Hepatocellular carcinoma (HCC) is one of the deadliest malignancies worldwide, with late detection, ineffective treatment and poor overall survival. Immunotherapy, including immune checkpoint inhibitor (ICI) therapy, holds great potential for treatment of HCC. Although some patients respond...

Full description

Bibliographic Details

Published in:	BMC Medical Genomics
Main Authors:	Xinyao Hu, Dan Li, Hua Zhu, Tao Yu, Xiaoxing Xiong, Ximing Xu
Format:	Article
Language:	English
Published:	BMC 2023-08-01
Subjects:	HCC ATP6V1F Immunotherapy TME Immune cell infiltrates
Online Access:	https://doi.org/10.1186/s12920-023-01624-6